| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
2 companies
Waldemar Priebe last filed a Form 4 in December 2022, as 10% Owner at MBRX. The filings on record cover 2 companies. Waldemar Priebe's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Waldemar Priebe's trades have earned a strong insider score of 74/100 across 17 rated trades. Over a 12-month horizon, all 17 of those trades were profitable, with an average 12-month return of +55.1%.
At the last filing, the largest reported position was 2,781,573 shares of MBRX. The MBRX filings lean toward selling, a net 100,000 shares.
Waldemar Priebe has 4 Form 4 filings on record from August 2017 to December 2022, across 2 companies: CNS Pharmaceuticals (CNSP), 2020–2022; 10% Owner at Moleculin Biotech (MBRX), 2017–2020.
The 20 reported transactions were 18 open-market sales, 1 option or other derivative award and 1 other transaction.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $303K.
The largest open-market sale was 100,000 shares of MBRX at an average $1.70 on August 16, 2017, about $170K.
Shares as reported in the last Form 4 for each company; the most recent is from December 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.